Mice deficient in the p40 subunit are protected from colitis, and agents that interfere with p40 and the downstream pathways of both IL-12 and IL-23 are already in use, or are being evaluated as novel treatments, for the two major inflammatory bowel diseases (IBD), Crohn’s disease and Ulcerative Colitis [21]. Here, IL9 is linked to colitis.